484 related articles for article (PubMed ID: 32361219)
1. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
2. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
4. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
[TBL] [Abstract][Full Text] [Related]
8. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
[TBL] [Abstract][Full Text] [Related]
9. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
12. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
14. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
15. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
17. CAR T-cell therapy and critical care : A survival guide for medical emergency teams.
Messmer AS; Que YA; Schankin C; Banz Y; Bacher U; Novak U; Pabst T
Wien Klin Wochenschr; 2021 Dec; 133(23-24):1318-1325. PubMed ID: 34613477
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
19. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN
Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
